Global Information
회사소개 | 문의 | 위시리스트

DEL(DNA-Encoded Library) : 플랫폼 및 서비스 시장

DNA-Encoded Libraries: Platforms and Services Market

리서치사 ROOTS ANALYSIS
발행일 2020년 01월 상품 코드 919315
페이지 정보 영문 133 Pages
가격
US $ 4,899 ₩ 5,985,000 PDF by E-mail (Single User License)
US $ 7,999 ₩ 9,772,000 PDF by E-mail (Site License)
US $ 15,999 ₩ 19,545,000 PDF by E-mail (Enterprise License)


DEL(DNA-Encoded Library) : 플랫폼 및 서비스 시장 DNA-Encoded Libraries: Platforms and Services Market
발행일 : 2020년 01월 페이지 정보 : 영문 133 Pages

Drug Discovery 프로세스에 수반하는 복잡성으로 인해 의약품·바이오테크놀러지 부문의 R&D 지출은 해마다 증가하고 있으며, 2019년의 R&D비는 약 1820억 달러로 추계되고 있습니다. DEL(DNA-Encoded Library)은 라이브러리 사이즈, 비용, 기기 요구 등의 점에서 High Throughput Screening보다 우수하므로 대량 저분자화합물의 합성 및 스크리닝을 위한 첨단 병용약 Discovery 툴임이 실증되고 있습니다.

DEL(DNA-Encoded Library) 플랫폼 및 서비스 시장을 조사했으며, Drug Discovery 프로세스, DEL의 개요, 발전 경위, 이점·단점, 관련 사업자의 분포, 주요 기업의 개요, 기업간 제휴 동향, 사례 연구, 대형 제약기업의 구상, 시장 규모의 추이·예측 등을 정리하여 전해드립니다.

제1장 서문

제2장 개요

제3장 서론

  • 본 장의 개요
  • 약제 개발의 개요
  • Drug Discovery 프로세스
    • 표적 식별
    • 표적 밸리데이션
    • 히트 생성
      • High Throughput Screening
      • 프래그먼트 스크리닝
      • 가상 스크리닝
      • DEL(DNA-Encoded Library) 스크리닝
    • HTL(Hit-to-Lead)
    • 리드 최적화
  • DEL의 개요
    • 발전 경위
    • 라이브러리 구축의 인코딩 전략
    • 기존형 라이브러리·DEL의 비교
    • 주요 이점
    • 과제·제약
  • 향후 전망·시장 기회 영역

제4장 현재 시장 환경

  • 본 장의 개요
  • DEL : 전체 시장
    • 라이브러리 사이즈별
    • 약리학적 리드별
    • 라이브러리 합성 방법별
    • 치료 표적별
    • 치료 영역별
  • DEL : 개발업체 환경
    • 설립년별
    • 기업 규모별
    • 소재지별
    • 제공 서비스별
  • DEL : 지원 기업

제5장 제휴·협업

  • 본 장의 개요
  • 제휴 모델
  • DEL : 최근 제휴·협업
    • 제휴년별
    • 제휴 종류별
    • 제휴년·파트너 종류별
    • 가장 활발한 사업자
    • 가장 인기가 높은 DEL
    • 지역 분석

제6장 기업 개요

  • 본 장의 개요
  • HitGen
  • X-Chem
  • Vipergen
  • DyNAbind

제7장 사례 연구 : DEL을 이용한 생물학적 표적

  • 본 장의 개요
  • 암의 언드러거블(Undruggable) 표적
    • GPCR
    • GPCR 표적약 : 임상·전임상 단계의 분자 리스트
  • DNA 수복 표적
    • PARP 저해제 : 개요
    • PARP 저해제 : 임상·전임상 단계의 분자 리스트
  • 기타 표적

제8장 대형 제약기업의 구상

  • 본 장의 개요
  • 주요 기업
  • Amgen
  • AstraZeneca
  • GSK
  • Novartis
  • Pfizer
  • Roche

제9장 DEL 시장 : 시장 기회 분석

  • 본 장의 개요
  • 전제 요인
  • 예측 방법
  • DEL 라이선싱 시장 : 선불금·마일스톤금(Milestone Payments)
  • DEL 시장 : 새로운 시장 기회

제10장 결론

제11장 전문가의 견해

제12장 부록 1 : 도표

제13장 부록 2 : 기업·조직 리스트

KSA 20.02.13

List Of Figures

  • Figure 3.1. Drug Discovery and Development Timeline
  • Figure 3.2. Drug Discovery Process
  • Figure 3.3. Concept of DNA-Encoded Libraries
  • Figure 3.4. Historical Evolution of DNA-Encoded Libraries
  • Figure 3.5. Encoding Strategies for Constructing DNA-Encoded Libraries
  • Figure 3.6. Comparison of Traditional Libraries and DNA-Encoded Libraries
  • Figure 3.7. Advantages of DNA-Encoded Libraries
  • Figure 3.8. Limitations of DNA-Encoded Libraries
  • Figure 4.1. DNA-Encoded Libraries: Distribution by Library Size
  • Figure 4.2. DNA-Encoded Libraries: Distribution by Type of Pharmacological Lead
  • Figure 4.3. DNA-Encoded Libraries: Distribution by Method of Library Synthesis
  • Figure 4.4. DNA-Encoded Libraries: Distribution by Therapeutic Target
  • Figure 4.5. DNA-Encoded Libraries: Distribution by Therapeutic Area
  • Figure 4.6. DNA-Encoded Libraries: Distribution by Year of Establishment
  • Figure 4.7. DNA-Encoded Libraries: Distribution by Company Size
  • Figure 4.8. DNA-Encoded Libraries: Distribution by Geographical Location
  • Figure 4.9. DNA-Encoded Libraries: Distribution by Year of Establishment, Company Size and Geographical Location
  • Figure 4.10. DNA-Encoded Libraries: Distribution by Type of Service Offered
  • Figure 4.11. DNA-Encoded Libraries: Geographical Landscape of Developers by Type of Service Offering
  • Figure 5.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2019 (till October)
  • Figure 5.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 5.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
  • Figure 5.4. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 5.5. Most Active Players: Distribution by Number of Partnerships
  • Figure 5.6. Most Popular Technologies: Distribution by Number of Partnerships
  • Figure 5.7. Most Active Players: Geographical Distribution by Number of Partnerships
  • Figure 5.8. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 6.1. HitGen: Service Portfolio
  • Figure 6.2. HitGen: DNA-Encoded Library Synthesis
  • Figure 6.3. HitGen: DNA-Encoded Library Steps
  • Figure 6.4. X-Chem: DNA-Encoded Library Synthesis
  • Figure 6.5. Vipergen: Service Portfolio
  • Figure 6.6. Vipergen: DNA-Encoded Library Synthesis
  • Figure 6.7. Vipergen: MedChem HTS versus YoctoReactor
  • Figure 6.8. DyNAbind: Service Portfolio
  • Figure 8.1. Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
  • Figure 9.1. Licensing Agreements: Distribution of Financial Components
  • Figure 9.2. Library Licensing Deal: Payment Structure
  • Figure 9.3. DNA-Encoded Libraries: Platforms and Services Market: Upfront and Milestone Payments, 2020, 2025 and 2030 (USD Million)
  • Figure 9.4. Case Study: Popular Drug Discovery Methods, 2016-2017

List Of Tables

  • Table 4.1. DNA-Encoded Libraries: Technology Overview
  • Table 4.2. DNA-Encoded Libraries: Methods of Library Synthesis
  • Table 4.3. DNA-Encoded Libraries: Developer Overview
  • Table 4.4. DNA-Encoded Libraries: Type of Service Offered
  • Table 4.5. DNA-Encoded Libraries: Supporting Companies
  • Table 5.1. DNA-Encoded Libraries: Partnerships and Collaborations, 2010-2019
  • Table 6.1. HitGen: Key Highlights
  • Table 6.2. HitGen: Recent Developments and Future Outlook
  • Table 6.3. X-Chem: Company Snapshot
  • Table 6.4. X-Chem: Recent Developments and Future Outlook
  • Table 6.5. Vipergen: Company Snapshot
  • Table 6.6. Vipergen: Recent Developments and Future Outlook
  • Table 6.7. DyNAbind: Company Snapshot
  • Table 6.8. DyNAbind: Recent Developments and Future Outlook
  • Table 7.1. GPCR's: List of Clinical / Preclinical Molecules
  • Table 7.2. PARP Inhibitors: List of Clinical / Preclinical Molecules
  • Table 8.1. Amgen: Company Snapshot
  • Table 8.2. AstraZeneca: Company Snapshot
  • Table 8.3. GSK: Company Snapshot
  • Table 8.4. Novartis: Company Snapshot
  • Table 8.5. Pfizer: Company Snapshot
  • Table 8.6. Roche: Company Snapshot
  • Table 9.1. Library Licensing Deal: Tranches of Milestone Payments
  • Table 9.2. DNA-Encoded Libraries: Average Upfront Payments and Average Milestone Payments (USD Million)
  • Table 10.1. DNA-Encoded Libraries: Summary of the Competitive Insights
  • Table 12.1. DNA-Encoded Libraries: Distribution by Library Size
  • Table 12.2. DNA-Encoded Libraries: Distribution by Type of Pharmacological Lead
  • Table 12.3. DNA-Encoded Libraries: Distribution by Method of Library Synthesis
  • Table 12.4. DNA-Encoded Libraries: Distribution by Therapeutic Target
  • Table 12.5. DNA-Encoded Libraries: Distribution by Therapeutic Area
  • Table 12.6. DNA-Encoded Libraries: Distribution by Year of Establishment
  • Table 12.7. DNA-Encoded Libraries: Distribution by Company Size
  • Table 12.8. DNA-Encoded Libraries: Distribution by Geographical Location
  • Table 12.9. DNA-Encoded Libraries: Distribution by Type of Service Offered
  • Table 12.10. Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2019
  • Table 12.11. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 12.12. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
  • Table 12.13. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 12.14. Partnerships and Collaborations: Most Active Players
  • Table 12.15. Most Popular Technologies: Distribution by Number of Partnerships
  • Table 12.16. Partnerships and Collaborations: Analysis by Local and International Distribution
  • Table 12.17. DNA-Encoded Libraries: Platforms and Services Market: Upfront and Milestone Payments, 2020, 2025 and 2030 (USD Million)
  • Table 12.18. Case Study: Popular Drug Discovery Methods, 2016-2017

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. AbbVie
  • 2. Abilita Bio
  • 3. Actelion Pharmaceuticals
  • 4. Aduro Biotech
  • 5. Alexion Pharmaceuticals
  • 6. Almirall
  • 7. Amgen
  • 8. AMRI
  • 9. Arvinas
  • 10. Asinex
  • 11. Astellas Pharma
  • 12. AstraZeneca
  • 13. BASF
  • 14. Bayer
  • 15. BeiGene
  • 16. Biogen
  • 17. Biokine Therapeutics
  • 18. BioLineRx
  • 19. Biotage
  • 20. Bristol-Myers Squibb
  • 21. BOC Sciences
  • 22. Boehringer Ingelheim
  • 23. Broad Institute
  • 24. California Institute for Biomedical Research (Calibr)
  • 25. Cancer Research Technology
  • 26. Cantex Pharmaceuticals
  • 27. Central European Institute of Technology (CEITEC)
  • 28. Charles River Laboratories
  • 29. Checkpoint Therapeutics
  • 30. ChemAxon
  • 31. ChemRoutes
  • 32. Chem-Space
  • 33. Circle Pharma
  • 34. Clovis Oncology
  • 35. Cocrystal Pharma
  • 36. Columbia University
  • 37. ComInnex
  • 38. Confo Therapeutics
  • 39. Cyclofluidic
  • 40. Daiichi Sankyo
  • 41. DELopen
  • 42. Deluge Biotechnologies
  • 43. DiCE Molecules
  • 44. DNA Technologies and Expression Analysis Core, University of California
  • 45. DyNAbind
  • 46. Edelris
  • 47. Eli Lilly
  • 48. Enamine
  • 49. Ensemble Therapeutics
  • 50. ETH Zurich
  • 51. Exo therapeutics
  • 52. FORMA Therapeutics
  • 53. Galapagos
  • 54. Genentech
  • 55. Gilead Sciences
  • 56. Global Blood Therapeutics
  • 57. GlycoMimetics
  • 58. Heptares Therapeutics
  • 59. HitGen
  • 60. HotSpot Therapeutics
  • 61. InterX Technologies
  • 62. Janssen Biotech
  • 63. Jeil Pharmaceutical
  • 64. Jiangsu Hengrui Medicine
  • 65. Johnson & Johnson
  • 66. Kymera Therapeutics
  • 67. LEO Pharma
  • 68. Liverpool ChiroChem
  • 69. LG Chem
  • 70. LGC, Bioresearch Technologies
  • 71. Macroceutics
  • 72. Maruho
  • 73. MD Anderson Cancer Center
  • 74. Medivation
  • 75. Merck
  • 76. Mitsubishi Tanabe Pharma
  • 77. Navitor Pharmaceuticals
  • 78. NetVation
  • 79. Northwestern University
  • 80. Novartis
  • 81. Nuevolution
  • 82. Nurix Therapeutics
  • 83. OMass Therapeutics
  • 84. Ono Pharmaceutical
  • 85. Orbit Discovery
  • 86. Otsuka Pharmaceutical
  • 87. Pfizer
  • 88. Pharmaceutical Product Development
  • 89. Pharmaron
  • 90. Philochem
  • 91. PhoreMost
  • 92. PhyNexus
  • 93. Plexium
  • 94. Polyphor
  • 95. Praecis Pharmaceuticals
  • 96. PROvendis
  • 97. PsyBrain
  • 98. Radikal Therapeutics
  • 99. Roche
  • 100. Sanofi
  • 101. Servier
  • 102. Simcere Pharmaceutical
  • 103. Sun Pharma Advanced Research Company (SPARC)
  • 104. SpiroChem
  • 105. Taiho Pharmaceutical
  • 106. Takeda Pharmaceutical
  • 107. Tasly
  • 108. Tesaro
  • 109. The Scripps Research Institute
  • 110. University of California
  • 111. University of Manchester
  • 112. University of Pennsylvania
  • 113. Vertex Pharmaceuticals
  • 114. Vipergen
  • 115. Viva Biotech
  • 116. Warp Drive Bio
  • 117. WuXi AppTec
  • 118. X-Biotix Therapeutics
  • 119. X-Chem
  • 120. X4 Pharmaceuticals

Example Insights:

In the short term, the opportunity is likely to be driven by library platform licensing activity; this activity is likely to increase as the industry realizes the capability of DNA-encoded libraries to discover high-value therapeutic leads.

Overview:

The process of drug development, beginning from the discovery of a molecule to its commercial launch, takes around 10-15 years and capital investments worth USD 4-10 billion. It is a well-known fact that only a small proportion of molecules, which are selected for further investigation during the initial stages of research, are actually translated into product candidates. Given the complexities involved in the drug discovery process, the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has steadily increased over time. Specifically, in 2019, the R&D spending was estimated to be around USD 182 billion; over 16,000 drug molecules were reportedly evaluated during the year. The industry is presently under tremendous pressure not only to identify ways to mitigate the risks of failure of drug discovery programs but also to meet the expectations of a growing patient population.

DNA-encoded libraries (also known as DELs), owing to their advantages (such as library size, cost and equipment needs) over high-throughput screening, have demonstrated to be a sophisticated combinatorial drug discovery tool for synthesis and screening of large collections of small molecule compounds. Interestingly, DNA-encoded libraries encompassing as high as 40 trillion different molecules have been developed, enabling screening, hit identification and discovery of pharmacological leads (including macrocycles, natural products and small molecules) against undruggable and unique targets using a single library and accelerating the process of drug development. Moreover, introduction of automated screening of small organic ligands using DNA-encoded chemical libraries has enabled identification of potential lead molecules within a time duration of 10 days.

Several mid-sized to large companies have undertaken initiatives towards building in-house DNA-encoded library technology. In addition, players have forged strategic alliances with service providers for accessing the latter's DNA-encoded libraries for the purpose of drug discovery. The growing number of drug discovery projects, coupled to the rapid progression of molecules through various stages of drug discovery, is expected to continue to increase demand for such advanced drug discovery tools.

Scope of the Report:

The “DNA-Encoded Libraries: Platforms and Services Market” report features an extensive study of the current landscape and the untapped opportunities these DNA-encoded likely to bring in the field of drug discovery. In addition to other elements, the report includes:

  • An overview of the current market landscape of DNA-encoded libraries, featuring details on the type of pharmacological lead (macrocycles, natural products, peptides and small molecules), library size, method of library synthesis, type of therapeutic target and type of therapeutic area.
  • An overview of the landscape of DNA-encoded library developers and analysis based on parameters, such as year of establishment, company size, type of service offered (screening service / hit identification, hit optimization / validation, custom library design / synthesis, in-house drug development and DNA-encoded library service kits) and geographical location.
  • A detailed analysis of the partnerships related to DNA-encoded libraries, which have been established in the recent past, covering research collaborations, research and development agreements, licensing agreements, acquisitions, distribution agreements, service alliances, and other relevant agreements.
  • Elaborate profiles of the prominent service providers engaged in this domain. Each profile features a brief overview of the company, information on its service portfolio, DNA-encoded library portfolio, recent developments and an informed future outlook.
  • A brief overview of the initiatives taken by big pharma companies (such as Amgen, AstraZeneca, GSK, Novartis, Pfizer and Roche) involved in this domain, highlighting the key focus areas of these players along with information on the recent deals inked with the DNA-encoded library providers (if available) . It also features company snapshots for each of the above-mentioned companies

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the DNA-encoded libraries developers' market and its evolution in the short-mid-term and long term.

Chapter 3 provides an introduction to the process of drug discovery and development. In addition, the chapter focuses on the concept of DNA-encoded libraries with information on the evolution of these libraries, advantages over other conventional drug discovery methods and the challenges associated with the same. It also features a brief discussion on the opportunities and the likely future trends in this field.

Chapter 4 provides a detailed overview of the current market landscape of DNA-encoded libraries, featuring information on type of pharmacological lead (macrocycles, natural products, peptides and small molecules), library size, method of library synthesis, type of therapeutic target and type of therapeutic area. In addition, the chapter provides an overview of DNA-encoded libraries developers and analysis based on parameters, such as year of establishment, company size, type of service offered (screening service / hit identification, hit optimization / validation, custom library design / synthesis, in-house drug development and DNA-encoded library service kits) and geographical location.

Chapter 5 features an in-depth analysis and discussion on the various collaborations and partnerships inked between the players in the recent past; these include research collaborations, research and development agreements, licensing agreements, acquisitions, distribution agreements, service alliances, and other relevant agreements.

Chapter 6 provides detailed profiles of the prominent service providers engaged in this domain. Each profile features a brief overview of company, information on its services associated with their DNA-Encoded library, recent developments and an informed future outlook.

Chapter 7 presents a case study on the therapeutic target(s) against which the DNA-encoded libraries are capable of identifying potential leads. Examples of such targets include undruggable cancer targets (special focus on GPCRs) , DNA repair targets (special focus on PARP inhibitors) and other targets (such as alpha-1-acid glycoprotein (AGP), carbonic anhydrase IX, mitogen-activated protein kinase 14 (MAPK14), Neurokinin 3 (NK3), receptor-interacting protein 1 kinase (RIP1), soluble epoxide hydrolase (sEH) and interleukin 2).

Chapter 8 presents overview of the initiatives taken by big pharma companies (such as Amgen, AstraZeneca, GSK, Novartis, Pfizer and Roche) involved in this domain, highlighting the key focus areas of these players along with information on the recent deals inked with the DNA-encoded library providers (if available). It also features company snapshots for each of the above-mentioned companies.

Chapter 9 presents an insightful market forecast analysis, highlighting likely growth of DNA-encoded libraries market till the year 2030, on the basis of likely licensing deal structures and agreements that are expected to be signed in the foreseen future.

Chapter 10 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it highlights the various evolutionary trends that are likely to determine the future of the DNA-encoded library screening approach.

Chapter 11 is a collection of interview transcripts of the discussions held with key stakeholders in this market.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Drug Development
  • 3.3. Drug Discovery Process
    • 3.3.1. Target Identification
    • 3.3.2. Target Validation
    • 3.3.3. Hit Generation
      • 3.3.3.1. High-Throughput Screening
      • 3.3.3.2. Fragment Based Screening
      • 3.3.3.3. Virtual Screening
      • 3.3.3.4. DNA-Encoded Library-based Screening
    • 3.3.4. Hit-to-Lead
    • 3.3.5. Lead Optimization
  • 3.4. Overview of DNA-Encoded Libraries
    • 3.4.1. Historical Evolution
    • 3.4.2. Encoding Strategies for Library Construction
    • 3.4.3. Comparison of Traditional Libraries and DNA-Encoded Libraries
    • 3.4.4. Key Advantages
    • 3.4.5. Challenges and Limitations
  • 3.5. Future Perspectives and Opportunity Areas

4. CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. DNA-Encoded Libraries: Overall Market Landscape
    • 4.2.1. Analysis by Library Size
    • 4.2.2. Analysis by Type of Pharmacological Lead
    • 4.2.3. Analysis by Method of Library Synthesis
    • 4.2.4. Analysis by Therapeutic Target
    • 4.2.5. Analysis by Therapeutic Area
  • 4.3. DNA-Encoded Libraries: Developer Landscape
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Geographical Location
    • 4.3.4. Analysis by Type of Service Offered
  • 4.4. DNA-Encoded Libraries: Supporting Companies

5. PARTNERSHIPS AND COLLABORATIONS

  • 5.1. Chapter Overview
  • 5.2. Partnership Models
  • 5.3. DNA-Encoded Libraries: Recent Partnerships and Collaborations
    • 5.3.1. Analysis by Year of Partnership
    • 5.3.2. Analysis by Type of Partnership
    • 5.3.3. Analysis by Year of Partnership and Type of Partner
    • 5.3.4. Most Active Players: Analysis by Number of Partnerships
    • 5.3.5. Most Popular DNA-Encoded Libraries: Analysis by Number of Partnerships
    • 5.3.6. Regional Analysis
      • 5.3.6.1. Most Active Players: Analysis by Local and International Agreements
      • 5.3.6.2. Intercontinental and Intracontinental Agreements

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. HitGen
    • 6.2.1. Company Overview
    • 6.2.2. Service Portfolio
      • 6.2.2.1. HitGen's DNA-Encoded Libraries
    • 6.2.3. Recent Developments and Future Outlook
  • 6.3. X-Chem
    • 6.3.1. Company Overview
    • 6.3.2. Service Portfolio
      • 6.3.2.1. X-Chem's DNA-Encoded Libraries
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. Vipergen
    • 6.4.1. Company Overview
    • 6.4.2. Service Portfolio
      • 6.4.2.1. Vipergen's DNA-Encoded Libraries
    • 6.4.3. Recent Developments and Future Outlook
  • 6.5. DyNAbind
    • 6.5.1. Company Overview
    • 6.5.2. Service Portfolio
      • 6.5.2.1. DyNAbind's DNA-Encoded Libraries
    • 6.5.3. Recent Developments and Future Outlook

7. CASE STUDY: LIKELY BIOLOGICAL TARGETS FOR DRUG DISCOVERY USING DNA-ENCODED LIBRARIES

  • 7.1. Chapter Overview
  • 7.2. Undruggable Cancer Targets
    • 7.2.1. G protein-coupled receptors (GPCRs)
    • 7.2.2. GPCRs Targeting Drugs: List of Clinical / Preclinical Molecules
  • 7.3. DNA Repair Targets
    • 7.3.1. poly ADP ribose polymerase (PARP) Inhibitors: Overview
    • 7.3.2. PARP Inhibitors: List of Clinical / Preclinical Molecules
  • 7.4. Other Targets

8. BIG PHARMA INITIATIVES: DNA-ENCODED LIBRARIES

  • 8.1. Chapter Overview
  • 8.2. Top Pharmaceutical Companies
  • 8.3. Amgen
    • 8.3.1. Company Snapshot
    • 8.3.2. Initiatives by Amgen
  • 8.4. AstraZeneca
    • 8.4.1. Company Snapshot
    • 8.4.2. Initiatives by AstraZeneca
  • 8.5. GSK
    • 8.5.1. Company Snapshot
    • 8.5.2. Initiatives by GSK
  • 8.6. Novartis
    • 8.6.1. Company Snapshot
    • 8.6.2. Initiatives by Novartis
  • 8.7. Pfizer
    • 8.7.1. Company Snapshot
    • 8.7.2. Initiatives by Pfizer
  • 8.8. Roche
    • 8.8.1. Company Snapshot
    • 8.8.2. Initiatives by Roche

9. DNA-ENCODED LIBRARY MARKET: OPPORTUNITY ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Key Assumptions and Input Data
  • 9.3. Forecast Methodology
  • 9.4. DNA-Encoded Libraries Licensing Market: Upfront and Milestone Payments, 2020, 2025 And 2030
  • 9.5. DNA-Encoded Libraries Market: Additional Opportunity

10. CONCLUDING REMARKS

  • 10.1. Chapter Overview
  • 10.2. Key Takeaways

11. EXECUTIVE INSIGHTS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Back to Top
전화 문의
F A Q